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Abstract: Urinary tract infections (UTI) are common among the female population. It has been 
calculated that about one-third of adult women have experienced an episode of symptomatic 
cystitis at least once. It is also common for these episodes to recur. If predisposing factors are 
not identified and removed, UTI can lead to more serious consequences, in particular kidney 
damage and renal failure. The aim of this review was to analyze the factors more commonly 
correlated with UTI in women, and to see what possible solutions are currently used in general 
practice and specialized areas, as well as those still under investigation. A good understanding 
of the possible pathogenic factors contributing to the development of UTI and its recurrence 
will help the general practitioner to interview the patient, search for causes that would otherwise 
remain undiscovered, and to identify the correct therapeutic strategy.
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Etiology
Escherichia coli and Staphylococcus saprophyticus account for about 80% of 
  community-acquired uncomplicated urinary infections (UTI), particularly in women 
under 50 years of age.1,2 E. coli is a Gram-negative commensal of the distal colon 
which also harbors other anaerobic bacteria, including Bacteroides and   Bifidobacteria.3 
Uropathogenic E. coli differs from intestinal pathogenic E. coli with regard to the pres-
ence of specific virulence factors. Among the various serotypes of E. coli, 01, 02, 04, 
06, 07, 08, 016, 018, 025, and 075 are commonly recovered from patients with UTI.4 
About 80% of uropathogenic E. coli express P fimbriae which anchor to the glycolipid 
of the outer membranes of urothelial cells localized in the kidney.5,6 P fimbriae are 
frequently associated with cases of acute pyelonephritis.
Another important virulence factor is Type 1 fimbriae. These are very important 
in the mechanism of bacterial adhesion to the uroepithelium. They are comprised 
of several subunits, the most important of which is an adhesion protein known as 
FimH which plays a principal role in the pathogenic mechanism of E. coli at the 
level of the urinary tract. It mediates both cellular invasion of E. coli and adhesion to 
mannose-containing glycoproteins.7,8 In vivo and in vitro studies have shown that the 
  pathogenicity of E. coli is mainly related to mechanisms of colonization and invasion 
of the bladder epithelium and the ability to form intracellular bacterial communities. 
FimH enables uropathogenic E. coli to escape the innate immune response by internal-
ization within urothelial cells, mediated by the activation of host signal transduction 
cascades via protein tyrosine kinases, phosphoinositide-3 kinase, and localized host 
actin cytoskeletal rearrangements.9 After invasion, E. coli is harbored within vesicles International Journal of General Medicine 2011:4 submit your manuscript | www.dovepress.com
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inside infected urothelial cells,10 from which it cannot be 
expelled. FimH also plays a role in the modulation of apop-
tosis in epithelial cells and in the mechanisms of cytoplasmic 
replication. Therefore, it is a very powerful factor in invasion 
and virulence. When FimH is not present, the uroepithelium 
is usually able to clear E. coli colonies via expulsion and 
mechanisms of the cellular immune response.
S. saprophyticus is a common UTI pathogen in younger 
women. It is reported to colonize the rectum and, to a lesser 
extent, the cervix and urethra in a small proportion of women.11 
E. coli is the main organism responsible for nosocomial UTI, 
but other Gram-negative pathogens, including Pseudomonas 
spp, Enterobacter spp, Serratia spp,   Citrobacter spp, and 
urease-producing Klebsiella spp, Proteus spp, Corynebac-
terium urealyticum, and Providencia spp are also involved 
in this type of infection.12 They are commonly involved in 
nosocomial UTI due to the inability of antibiotics to penetrate 
into the biofilm formed around and within the infectious 
stone.13 Also, Gram-positive bacteria, including Enterococcus 
spp and Staphylococcus spp, can cause nosocomial UTI due 
to selective pressure from the antimicrobial agents used in 
hospitalized patients. Anaerobic bacteria are also described 
in UTI, but their role is not well-defined.14
Also increasing are the numbers of fungal UTI, par-
ticularly those caused by Candida spp, and, to a lesser 
extent, by Aspergillus spp and Cryptococcus neoformans. 
In one study, positivity for Candida spp was found in 5% of 
urine specimens from a general hospital and in 10% from 
a tertiary-level care center.15 Most UTI caused by Candida 
spp are associated with the use of indwelling urinary devices, 
including Foley catheters, internal stents, and percutaneous 
nephrostomy drains. Diabetics are particularly prone to 
fungal UTI.16 Normally this kind of infection is acquired by 
patients with severe neutropenia, drug abuse, recent surgery 
(chest, abdomen), and systemic infection.
Risk factors
Immune response
The principal mechanism of defense against infectious agents 
in the urinary tract lies in the innate immune response.   Animal 
models have identified a subgroup of toll-like receptors as 
the primary effectors in the pathway of response to noxious 
agents in the urinary tract.17 The binding of antigenic deter-
minants of pathogenic strains, as happens with P   fimbriae 
and Type 1 fimbriae for uropathogenic E. coli, activates 
a signaling cascade, leading to the production of cytok-
ines, including interleukin (Il)-6, IL-8, and tumor necrosis 
factor.18 The same mechanism is not activated against the 
  determinants of nonpathogenic strains, raising the possibility 
that there are also control mechanisms activating a level of 
tolerance to symbionts.19 With regard to recurrence of UTI, 
a subgroup of toll-like receptors, ie, TLR-4, was investigated 
and shown to play an important role in the host response to 
uropathogens. Mice in experimental models and children not 
expressing TLR-4 have been shown to lack responsivity to 
uropathogenic E. coli strains, resulting in development of 
asymptomatic bacteriuria, while individuals with moderately 
reduced expression of TRL-4 tend to develop asymptomatic 
bacteriuria after a first symptomatic episode of UTI.20
After binding of uropathogens to the receptor, the main 
cytokine involved in the response is IL-8, which binds to 
the CXCR-1 receptor on the neutrophil plasma membrane. 
CXCR1 mediates the migration of uropathogens through 
the urothelial wall, leading to pyuria, ie, the macroscopic 
presence of pus in the urine. IL-8 levels in the blood have 
been demonstrated to correlate positively with the number 
of neutrophils found in the urine during infection.21
CXCR1 has also been suggested to play a role in the suscep-
tibility of individuals to recurrent UTI. In particular, the tendency 
of children with low levels of these receptors to develop recur-
rent pyelonephritis has been established.22,23   Polymorphisms of 
CXCR1 were recently demonstrated, and   studies are underway 
to see whether these qualitative variants are related to suscepti-
bility to recurrent UTIs, with the   possibility of either genetically 
dominant or recessive transmission.24
Anatomical structure
Anatomical factors and alterations also play an important 
role in the pathogenesis of UTI in women. The shortness of 
the urethra, with its close relationship to the anus, makes it 
easy for bacteria to ascend in the urinary tract. In women, 
fecal-perineal-urethral contamination is the most probable 
explanation for infections caused by enteric bacteria, as 
demonstrated by experiments evaluating the genotype of 
E. coli strains causing UTI in women.4,25
In a case-control study, 100 women with recurrent UTI 
and 113 controls were investigated to determine whether 
there were differences in perineal anatomic measure-
ments, postvoid residual urine volume, or in urine voiding 
  characteristics. The distance from the urethra to the anus was 
significantly shorter in cases than in controls (4.8 cm and 
5.0 cm, respectively, P = 0.03). No other differences were 
identified between cases and controls. These data suggest that 
pelvic anatomical characteristics may play a role in predis-
posing young women to recurrent UTI, especially those who 
do not have exogenous risk factors for these infections.26International Journal of General Medicine 2011:4 submit your manuscript | www.dovepress.com
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Altered vaginal biota
Lactobacilli are the dominant bacteria in the vaginal biota 
and possess antimicrobial properties that regulate other 
urogenital microbiota by maintaining an acidic pH in the 
vagina and producing hydrogen peroxide.27 Incomplete cure 
and recurrence of genitourinary tract infection leads to a 
shift in the local flora from a predominance of lactobacilli 
to coliform uropathogens. In a study by Kirjavainen et al it 
was confirmed that, in bacterial vaginosis, the normal lac-
tobacillus microbiota of the vagina shifts to a more mixed 
composition, which is also typical during disease-free periods 
in women prone to UTI. While the vaginal flora were not 
dominated by the most common uropathogens per se, they 
were likely to be defective in terms of resisting infection 
because of the lack of colonization resistance-enhancing 
properties conferred by lactobacillus accumulation.28 The 
use of lactobacillus-containing probiotics has been suggested 
for the treatment and prophylaxis of bacterial urogenital 
infection. However, the results of UTI prophylaxis studies 
using lactobacilli remain inconclusive.29 An alteration in vagi-
nal flora is also observed during the postmenopausal period, 
because estrogens stimulate the proliferation of lactobacilli 
and reduce the local pH.30
Genetic factors
Some studies suggest that a family history of UTI in a 
first-degree relative increases the risk of recurrent UTI and 
pyelonephritis in women. This supports the idea of a genetic 
influence on defense mechanisms in the urogenital tract.30
The development of a symptomatic UTI depends on 
the balance between pathogen virulence and the host 
response to the pathogen. Polymorphism of receptors 
involved in the inflammation process seems to be involved 
in the degree of susceptibility to developing symptomatic 
UTI. Some authors have studied genetic polymorphism in 
asymptomatic   bacteriuria, a condition considered to be a 
risk factor for symptomatic urinary tract infections.31 As 
previously discussed, toll-like receptors are critical sensors 
of infection, and control many aspects of the host immune 
defense response. The toll-like receptor signaling pathway 
initiates a proinflammatory response. After binding to urothe-
lial cell receptors and expression of virulence factors by 
uropathogens (eg, Type 1 and P fimbriae), toll-like receptors 
are activated.   Subsequently, they activate the innate immune 
response, along with production of cytokines.18 Cytokines 
are essential to modulate the immune response. IL-8 is 
involved in neutrophil recruitment and activation by bind-
ing to the CXCR1 receptor.32 In a cross-sectional analysis of 
asymptomatic bacteriuria in 1261 women aged 18–49 years, 
originally enrolled as participants in a population-based 
case-control study of recurrent UTI and pyelonephritis, 
Hawn et al found that TLR2 and CXCR1 polymorphisms 
were associated with asymptomatic bacteriuria, and a CXCR1 
variant was associated with urinary CXCL-8 levels. These 
results suggest that genetic factors are associated with the 
early human bladder immune response prior to the develop-
ment of symptomatic UTI.33 Other studies found an asso-
ciation between UTI in adults and TLR1, TLR4, and TLR5 
  polymorphism.34 These data support the idea of a genetic 
component for increased susceptibility to UTI in women.
Blood groups
Several lines of evidence have suggested the role of blood 
group antigens as susceptibility factors for UTIs. P fimbriae 
recognize Gal1-4Ga1 and Ga1Na-3Gal1-4Ga1 as recep-
tors, which contain oligosaccharide sequences in the globo 
series of glycolipids.35 These are also human P and ABO 
blood group antigens. Individuals with the P1 antigen are 
more predisposed to invasion by P fimbriated microorgan-
isms (mannose-resistant hemagglutination-positive strains). 
Patients with the negative P1 antigen express a smaller 
amount of receptors for P fimbriated E. coli, so that attach-
ment during passage through the boundary layer seems to 
be more difficult. It could be concluded that the existence 
of the P1 antigen may be a gap in the protective mechanism 
and could indicate an increased susceptibility to UTI.36 
Women with a history of recurrent UTI are three to four 
times more frequently found to be nonsecretor phenotypes 
of the ABO histo-blood group than women without such a 
history.37 Furthermore, uroepithelial cells from nonsecretor 
women show enhanced adherence of uropathogenic E. coli 
compared with secretor women. Recent data suggest that the 
biochemic explanation for increased adherence of E. coli to 
nonsecretor uroepithelial cells and their propensity to develop 
recurrent UTI may be the presence of a unique globo series 
of glycolipid receptors selectively expressed by nonsecretor 
epithelial cells that bind uropathogenic E. coli.38
Pregnancy
In a prospective study by Haylen et al 1140 women aged 
18–98 years were examined for recurrent UTI in different 
physiologic and pathologic conditions.39 A correlation was 
observed between nulliparity and recurrent UTI, particularly 
in woman younger than 50 years. The authors suggested that 
stretch and relaxation of the birth canal caused by pregnancy 
and delivery may be beneficial in preventing recurrent UTI International Journal of General Medicine 2011:4 submit your manuscript | www.dovepress.com
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by reducing the frictional effect of intercourse.39 A reduced 
frequency of intercourse and number of sexual partners may 
also account for these findings. In this study, there was a 
positive relationship between recurrent UTI and a postvoid 
residual urine volume of .30 mL.
Pregnancy is associated with asymptomatic bacteriuria 
in 4%–7% of cases and pyelonephritis in 0.5%–2%.40 Many 
studies have reported that pyelonephritis is more common 
during the second half of pregnancy.41 This is thought to 
result from increasing mechanical compression by the 
enlarging uterus. A history of recurrent UTI, diabetes, and 
anatomical abnormalities of the urinary tract increase the 
risk of developing a UTI during pregnancy.42 One of the 
most important risk factors for symptomatic infection is 
asymptomatic bacteriuria. Asymptomatic bacteriuria is the 
main risk factor for development of acute pyelonephritis.43 
During pregnancy, development of UTI is correlated with 
stasis of urine in the ureters, which impairs emptying of the 
bladder, with an increased postvoid residual urine volume, 
vesicoureteral reflux, and increased urinary pH.44
Menopause
The incidence of UTI in women increases with advancing age. 
Bacteriuria occurs in about 10%–15% of women aged 65–70 
years and in 20%–50% of women aged over 80 years.45 These 
values are higher than the 5% rate of bacteriuria reported in 
premenopausal women. In a study conducted by Raz et al46 in 
a group of 149 postmenopausal women, a strong association 
was noticed between anatomical and functional alterations 
of bladder emptying and recurrent UTI. Inherited factors and 
a history of premenopausal UTI have also been suggested 
as predisposing factors for the development of recurrent 
UTI. After menopause, there is a significant reduction in 
estrogen secretion by the ovary, which is often associated 
with vaginal   atrophy. Estrogens stimulate proliferation of 
Lactobacillus in the vaginal epithelium, causing reduction 
of vaginal pH, thereby preventing vaginal colonization by 
  Enterobacteriaceae. In addition, the absence of estrogens 
decreases the volume of the vaginal muscles, resulting in 
slackness of the ligaments holding the uterus, pelvic floor, 
and bladder, resulting in prolapse of the internal genitalia. 
A placebo-controlled, double-blind study47 demonstrated a 
correlation between reduced estrogenic hormone levels after 
menopause and the development of recurrent UTI. Application 
of topical vaginal estrogens markedly reduced the incidence of 
recurrent UTI in this study. In older institutionalized women, 
the main factors for development of recurrent UTI are deterio-
ration in functional status and urethral catheterization.48
Diabetes
Diabetes is another condition correlated with the develop-
ment of asymptomatic bacteriuria and recurrent UTI.49 
In a multicenter study of 589 women aged 18–75 years and 
affected by either Type 1 or 2 diabetes, the risk of developing 
a symptomatic UTI was increased by the same risk factors as 
those in younger women (sexual intercourse and oral con-
traceptive use) for Type 1 diabetes and by the presence of 
asymptomatic bacteriuria for Type 2 diabetes.50 For Type 1 
diabetes mellitus, risk factors for asymptomatic bacteriuria 
included a longer duration of diabetes, peripheral neuropathy, 
and microalbuminuria. For Type 2 diabetes, the risk factors 
were higher age, microalbuminuria, and a recent symptomatic 
UTI.40 The same study showed a weak correlation between 
increased risk of UTI and poor regulation of diabetes, pres-
ence of diabetic cystopathy, neuropathy, microalbuminuria, 
or macrovascular complications. Glycosuria does not seem 
to be a risk factor for the development of asymptomatic bac-
teriuria or symptomatic UTI in vivo. Neuropathy involving 
the urinary tract may be a potential mechanism that could 
increase the risk of UTI in diabetics, because it may result in 
dysfunctional voiding and urinary retention. However, efforts 
to determine a relationship between high postvoid residual 
urine and increased risk of UTI have been   inconclusive. 
No relationship between diabetes and uropathogens has 
been observed. However, first episodes of asymptomatic 
bacteriuria seem to be less often caused by E. coli, and more 
often caused by Klebsiella and Enterococcus faecalis. This 
suggests that asymptomatic bacteriuria and symptomatic 
UTI may be different disease processes, and that bacterial 
colonization in the absence of symptoms differs in patients 
with diabetes.1
Dysfunctional voiding
A correlation has also been observed between recurrent 
UTI and dysfunctional voiding. Dysfunctional voiding is 
defined as abnormal bladder emptying in neurologically 
normal individuals, especially young women in whom there 
is increased external sphincter activity during voluntary 
  voiding. The etiology is unknown. It is thought to be a learned 
behavior due to adverse pelvic conditions, eg, inflammation 
or trauma.51 It could also be the result of voluntary with-
holding of urine, or it could be a primary abnormality with 
detrusor instability and a dyssynergic sphincter. Association 
between dysfunctional voiding and recurrent UTI has been 
documented.52 Dysfunctional voiding may disrupt laminar 
urine flow through the urethra, causing a UTI as bacteria are 
transferred back from the meatus to the bladder as a result International Journal of General Medicine 2011:4 submit your manuscript | www.dovepress.com
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of the “milk-back” phenomenon.53 Dysfunctional voiding 
is investigated classically by the use of videourodynamic 
studies,54 but perineal ultrasound has recently been proposed 
as a more helpful investigation.55
Intercourse-related issues
Several behaviors seem to be correlated with the development 
of recurrent UTI in healthy premenopausal women. In a case-
control multivariate analysis by Scholes et al independent risk 
factors for recurrent UTI included frequency of intercourse 
in the previous month, 12-month spermicide use, and a new 
sex partner in the previous year. Second in magnitude only 
to frequency of intercourse were two nonbehavioral risk 
factors that remained in the model, ie, age at first UTI being 
younger than 15 years and a history of UTI in the mother.56 
No associations were found between history of recurrent 
UTIs and pre- and postcoital voiding patterns, frequency of 
urination, delayed voiding habits, wiping patterns, douching, 
use of hot tubs, frequent use of pantyhose or tights, or body 
mass index. In a review done in 2007, Farage et al reviewed 
the relevant research. The studies failed to find significant 
associations between the use of panty liners and recurrence of 
vulvovaginal infections, either bacterial or Candida-related. 
Furthermore, the studies analyzed tended to reject the theory 
that use of these devices is theoretically capable of influenc-
ing genital health, pH, or wetness, making the individuals 
more subject to recurrences of infection.57 Also, the use of 
other tight underwear or clothes has not been demonstrated 
to correlate with higher rates of UTI.
Management
Antibiotic therapy
Management of UTI in women depends on a number of 
  factors. First, a distinction must be made between asymp-
tomatic and symptomatic infection. Bacteriuria is common 
in women, and its prevalence increases with advancing age. 
Treatment for this condition is not always considered nec-
essary but, in women, the possibility of pregnancy makes 
evaluation worthwhile, because asymptomatic bacteriuria 
is associated with an increased risk of pyelonephritis and 
adverse outcomes of pregnancy.58 However, a symptomatic 
urinary infection should always be treated because it is 
unlikely to resolve spontaneously.
Antibiotic therapy is an important part of the thera-
peutic strategy for UTI, although control of predisposing 
factors as far as possible and prophylaxis are also neces-
sary, in order to achieve complete resolution of infection. 
A therapeutic algorithm for the treatment of symptomatic 
UTI has been developed from evidence-based consensus 
by the   International Consultation on Urologic Diseases, a 
summary of which is available in the European Association 
of Urology guidelines.59
The increased antibiotic resistance seen in recent years 
suggests that the choice of antibiotic should be guided by cul-
ture and sensitivity assays. However, an empirical approach 
is still considered valid for community-acquired UTI in the 
absence of complicating factors, eg, pyelonephritis, chronic 
infection, and atypical symptoms.
To date, given that E. coli is the most common 
uropathogen,60 a first approach with single-dose fosfomycin 
trometamol 3 g, pivmecillinam 400 mg for three days, or nitro-
furantoin macrocrystals 100 mg twice daily for five days, is 
considered to be the first-line choices for empirical treatment 
of acute symptomatic uncomplicated UTI (both of the lower 
and upper urinary tract) in all European countries.61,62
Use of trimethoprim-sulfamethoxazole is nowadays limited 
because of widespread microbial resistance and should only 
be used in regions with a known low resistance rate (,20%) 
and after culture and sensitivity assay.63   However, in countries 
where resistance is low,   trimethoprim-sulfamethoxazole can 
still be a valid first-line antibiotic, and in many countries 
where its use has been limited for years, in consideration of 
the evidence-based international guidelines, the resistance 
rate has receded and made possible the reintroduction of this 
combination as a therapeutic strategy.
Although quinolones have high efficacy against the 
main genitourinary microorganisms, particularly in vitro, 
clinical trials have failed to demonstrate their superiority 
in eradicating infections in comparison with other drugs. 
Moreover, higher rates of side effects in comparison with the 
aforementioned drugs and their lower tolerability limit the use 
of quinolones as second-line therapy. Furthermore, surveys 
conducted in many European countries have already shown 
high resistance rates in E. coli strains for nalidixic acid and 
its derivatives (over 10% and up to 32.6% in Hungary).64 The 
quinolones are primarily indicated at higher doses for treat-
ment of pyelonephritis and more complicated infections when 
susceptibility testing is available. In case of known resistance 
to quinolones, aminoglycosides and carbapenem are the 
drugs of choice. In all cases of persistence of symptoms or 
early recurrence (within 2 weeks of the end of therapy), it is 
essential to choose another antibiotic based on culture and 
sensitivity assay.
There is particular concern about treatment of asymp-
tomatic and symptomatic bacteriuria during pregnancy. UTI 
in pregnancy exposes both the mother and fetus to a higher International Journal of General Medicine 2011:4 submit your manuscript | www.dovepress.com
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risk of complications, and the choice of therapy is obviously 
more limited. Aminopenicillins are commonly used in preg-
nancy because they are not considered to be teratogenic.65 
Amoxicillin is well-absorbed orally and is to date a main-
stay of treatment. Cephalosporins have also generally been 
considered to be safe options. However, some concern has 
been raised about the use of single agents because of case 
reports of ceftriaxone use during pregnancy and the possible 
development of kernicterus. Similarly, teratogenicity with 
cefaclor, cefalexin, and cefradine was noted in a surveillance 
study of over 4000 Michigan Medicaid recipients exposed 
to these agents.66 Cotrimoxazole is to be avoided because of 
its teratogenic effects resulting from interference with the 
metabolism of folic acid.
Antibiotic prophylaxis
After a single episode of UTI has resolved, the next step is 
to consider factors that could trigger a recurrence. This is 
particularly important in women, in whom urinary retention 
is very common. According to the fecal-perineal-urethral 
hypothesis, uropathogenic organisms resident in the rectal 
flora represent the reservoir for ascending UTI in women. 
Several factors have been claimed to be responsible for this, 
both anatomical and psychosocial, but all possible factors 
should be taken into account.
In a study of 86 women with dysfunctional voiding and 
recurrent UTI, Minardi et al reported a reduction in the 
recurrence rate after pelvic floor re-education with biofeed-
back, supporting the hypothesis that emptying disorders 
play an important role in the recurrence of UTI in women.67 
Costantini et al reported similar results using alpha-blockers 
in women with voiding problems. Thus, functional problems 
contributing to recurrence of urinary infections were also 
significantly reduced.68
When all attempts at modification of patient behavior and 
lifestyle have failed to resolve the problem of recurrence, it 
may be necessary to start antimicrobial prophylaxis. There 
are currently no guidelines by which to identify nonpregnant 
women who should receive antibiotic prophylaxis for UTI. 
Some authors suggest that two recurrences within 6 months 
after therapy or three episodes per year could be consid-
ered an indication to establish prophylaxis after treatment. 
However, the patient’s discomfort about the prospect of 
recurrence of symptoms should be taken into account when 
choosing whether or not to start prophylaxis. Several kinds 
of prophylactic regimens, including continuous, intermit-
tent, and postcoital administration, have proved to be useful 
in cases of recurrent uncomplicated cystitis. Reports from 
studies conducted with different regimens show that up to 
95% of recurrences resolve after 6 months of therapy.69 The 
antibiotics of choice for this purpose are nitrofurantoin, 
fosfomycin trometamol, cotrimoxazole, cephalosporins, 
and quinolones, all at lower than therapeutic dosages. In all 
cases, a prophylactic regimen should be initiated only after 
complete eradication of the original infection is confirmed 
by a negative urine culture, performed 1–2 weeks after the 
conclusion of primary therapy.
Nonantibiotic prophylaxis
Because antibiotic resistance is steadily increasing, 
alternative or additional prophylactic strategies have been 
investigated. In particular, research on potential dietary 
supplementation has focused on cranberry (Vaccinium 
macrocarpon) juice and its extracts, the benefits of which 
for reducing UTI recurrences have been known for a long 
time. Many trials have demonstrated its beneficial effects in 
women suffering from recurrent UTI, and reduction of UTI 
recurrence during pregnancy has also been observed. The 
mechanism of action is related to the active metabolite of 
cranberry, ie, proanthocyanidin A, which has been shown to 
be able to inhibit Type P fimbria-mediated E. coli adhesion 
to urothelial cells and induce deformation in both antibiotic-
susceptible and antibiotic-resistant bacterial strains, thus 
preventing bacterial adhesion to the urothelial layer.70,71
In a randomized clinical trial, a dose-dependent reduc-
tion of bacterial adhesion in response to administration 
of cranberry juice identified the minimum daily dose of 
proanthocyanidin A able to reduce urinary E. coli concen-
trations significantly to be 36 mg. Further studies have been 
conducted in women, and most of them have showed a 
significant decrease in reinfection rates, with some suggest-
ing superiority in comparison with antibiotic prophylaxis, 
although the level of evidence is still quite low.72
Studies aimed at identifying well-tolerated cranberry 
doses in different formulations are underway, and are 
demonstrating a significant improvement in overall   quality 
of life for patients treated with prophylactic doses of 
cranberry.73 It should be borne in mind that not all studies 
have adequately demonstrated the prophylactic activity of 
cranberry against recurrence of UTI. A randomized trial 
conducted by Barbosa et al in a large number of female 
adolescents treated after a first episode of acute UTI failed 
to identify a beneficial effect of cranberry. These investiga-
tors suggested, as a possible explanation, that the principal 
active ingredient may lie in other components used as addi-
tives in cranberry juice.74International Journal of General Medicine 2011:4 submit your manuscript | www.dovepress.com
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An important physiologically protective mechanism 
against UTI lies in the preservation of the equilibrium of 
the normal vaginal microbial population due to the presence 
of different Lactobacillus species. It has been observed that 
healthy proliferation of these microorganisms is able to 
prevent colonization by pathogens. In particular, in cases 
where physiological changes in mucosal trophism (reduction 
of vaginal glycogen and increase in the pH) occur, recurrent 
UTI is likely. Based on this consideration, and on the fact 
that dysmicrobisms in the female genitalia also predispose to 
urinary infections, several studies have investigated if intra-
vaginal Lactobacillus administration could prevent UTI.
Other studies in postmenopausal women have shown that 
intravaginal administration of estriol helps to re-establish the 
normal flora, thus playing a protective role.47 Although the 
numbers studied to date are still small, this approach seems 
to be promising. In one of these studies, 41 premenopausal 
women were randomized after antibiotic treatment to receive 
intravaginal probiotics or placebo twice weekly for 2 weeks 
and then at the end of each of the next 2 months,75 and showed 
a reduction in UTI recurrence rate by approximately half in 
the probiotic group (21% versus 47%).
Another study supporting this approach was conducted 
by Beerepoot et al76 in 252 postmenopausal women with 
recurrent UTI. After 12 months of prophylaxis with either 
trimethoprim-sulfamethoxazole or oral capsules contain-
ing 109 colony-forming units of L. rhamnosus GR-1 and 
L. reuteri RC-14, a reduction in recurrences of more than 
50% was seen following both treatments, with median times 
to the next episode of 6 and 3 months for the antibiotic and 
probiotic arms, respectively, while resistance following 
prophylaxis in the antibiotic group nearly doubled. No such 
increase occurred in the probiotic group. However, not all 
studies support this approach, because their findings appear 
to be very variable, depending on the stem used and on the 
administration methods.
A study conducted by Rönnqvist et al suggested the 
possibility of using Lactobacillus-impregnated panty   liners. 
Their work showed a reduction in the predisposition of 
women treated with lactobacilli to develop UTI caused by 
Group B streptococci, thus demonstrating the feasibility of 
this method.77
As in other fields of medicine, the suggestion of immuni-
zation for patients at increased risk of recurrent UTI has been 
raised. Studies using heat-inactivated strains of uropathogenic 
E. coli have shown a good response, with good tolerability 
in patients.78 However, heterogeneity of the possible strains 
causing UTI and our as yet incomplete understanding of the 
mechanisms underlying bacterial pathogenicity and the host 
response against them, has prevented licensing of a vaccine 
for use in patients at risk for recurrent UTI.
Advances in basic research have demonstrated a cor-
relation between the capacity to produce hexameric IgM 
in response to infection and development of permanent 
immunity in the organism.79 Differences in the subtypes of 
urothelial receptors have also been investigated and found to 
play an important role in the development of infection in the 
host, and are correlated with the degree of disease severity.22 
Research in this area is still experimental, and further studies 
are still required to completely understand the mechanisms of 
infection and immune response, and to develop an efficient 
prophylactic strategy against recurrent UTI.
Fungal infections
Consideration should be given to the presence of Candida 
spp in the urine (candiduria). The finding of Candida in the 
urine can frequently be the result of contamination during col-
lection of urine samples from patients with Candida resident 
on the external genitalia.80 Candiduria is a condition most 
often found in elderly, hospitalized, or immunocompromised 
patients.81 Candida albicans is the most common species 
isolated, accounting for more than half of all cases, followed 
by Candida glabrata and other Candida spp.14,82
Even if asymptomatic, candiduria should be considered 
as an expression of a serious underlying illness, and predis-
posing causes should be investigated and treated whenever 
possible. Identification of the source of candiduria could 
prove to be useful, but the diagnostic tools at our disposal 
are currently inadequate to enable correct diagnosis of the 
site of origin (upper or lower urinary tract, kidneys) that 
could aid effective treatment. Asymptomatic candiduria in 
the absence of complicating conditions is not considered to 
be an indication for treatment.83
The mainstay of antibiotic treatment for candiduria is the 
azolic compounds, mainly fluconazole 200 mg orally daily 
for 2 weeks.84 The use of amphotericin B, which is more 
toxic, is to be regarded as second-line and for intravesical 
irrigation in certain settings, because it does treat potential 
fungal spread to the upper urinary tract (or even worse, 
systemic spread).85
Catheterized patients
Another important issue is catheter-related UTI in women. 
Although indwelling catheters are a source of infection in 
both genders, extraluminal ascending UTI in the female is 
more common, due to anatomical factors, and again, the International Journal of General Medicine 2011:4 submit your manuscript | www.dovepress.com
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most common microbes are of fecal origin. Consideration 
of the role of biofilms surrounding indwelling catheters 
in long-term catheterized women is therefore necessary. 
Bacteria become highly resistant to most antibiotics via 
biofilms, which prevent antibiotics reaching the pathogenic 
microorganisms. Because adhesion of these microorganisms 
to catheters is related to the hydrophilicity of the material 
they are made of, an important first step in the prevention of 
bacterial colonization and biofilm formation is selection of 
poorly hydrophilic catheters, such as those made of silicon, 
and avoidance of latex catheters whenever possible.
Research is presently underway to develop catheters with 
antimicrobial properties, by using a mixture of antibiotic 
coatings on the surface of the catheters.86–88 Although experi-
mental research has demonstrated good activity of these com-
binations in preventing colonization, definitive clinical trials 
demonstrating superiority of medicated over conventional 
catheters are still lacking.89 However, there has been some 
evidence suggesting the efficacy of medicated catheters for 
reducing bacteriuria in the short-term setting.90
Several antibiotics have been tested for their ability to 
reduce the risk of biofilm formation. In a recent study by 
Desai et al application of a nitrofurazone coating showed 
significant activity against E. coli and E. faecalis strains in 
delaying microbial adherence, which is the first step in   biofilm 
formation.91 Other studies have also shown nitrofurazone to 
be useful against infection by Candida spp. Ciprofloxacin-
impregnated catheters were also tested, and similar results 
were reported for prevention of infection by Gram-negative 
bacteria during short-time catheterization and for prevention 
of UTI caused by Pseudomonas aeruginosa.92
Other antibiotics investigated in this setting include 
rifampicin and minocycline, which are currently used in the 
coating of central venous access systems, and some efforts 
have been made to extend this application to urinary devices, 
where they have been shown to reduce the rate of colonization 
by Gram-positive bacteria, but not the colonization rates for 
Gram-negative or fungal organisms.90,93 Of note, although the 
efficacy of nitrofurazone-coated catheters has been demon-
strated in the short term (less than 1 week), the activity of the 
rifampicin-minocycline combination has been demonstrated 
to be superior to no medication for up to 2 weeks. There are 
currently no data supporting the efficacy of antibacterial 
coatings on catheters in preventing bacterial colonization or 
biofilm formation for longer periods of time.
However, antibiotic prophylaxis when using long-term 
indwelling catheters is not generally recommended due to 
the unfavorable balance between the advantages and side 
effects of long-term therapy94 and the limited advantages 
of short-term catheterization in the absence of complicat-
ing factors (eg, surgical procedures).95 Because no other 
  measures have been shown to have a significant impact on 
the prevention of UTI in patients with long-term catheters, 
the recommendation at this time is vigilant monitoring of the 
urine and prompt initiation of effective therapy as the best 
way to prevent such complications.96
In conclusion, UTI is more difficult to treat in women 
than in men because of its multifactorial etiology and the 
limitations posed by the possibility of pregnancy. The first 
objective for the physician is to identify women at risk for 
recurrence of UTI as well as to recognize and remove indi-
vidual risk factors.
Communication with the patient
As mentioned earlier, recurrent UTI in women, rather than 
being just a sequence of isolated episodes that can be treated 
with appropriate antibiotic therapy, is often multifactorial. 
Thus, the most important step in treatment is identification of 
the causes leading to the problem. Clearly, communication 
between the female patient and her physician is paramount, 
but is not always easy because patients often underestimate 
their symptoms, or consider them too embarrassing to discuss 
with their doctor. However, when placed in a specialist set-
ting, women will often appear more uninhibited and more 
willing to discuss their symptoms.
Subsequently, many patients will delay correct diagnosis 
and therapeutic strategy, even though the problem could have 
been easily solved by their family physicians, resulting in 
higher social and personal costs. It is thus necessary for the 
physician to spend time speaking with patients reporting UTI 
symptoms in order to gain a better understanding of the causes 
of the UTI. Attention must be paid to potential diseases which 
can work as factors favoring reinfection, because they disturb 
the normal storage-voiding cycle or reduce body defenses. 
In particular, any neurologic condition must be taken into 
account, along with metabolic dysfunction (eg, diabetes), 
gynecological disorders, and known infectious diseases, eg, 
human immunodeficiency virus. Detailed inquiry should be 
made about daily urination habits and any possible changes 
that could have occurred with time with regard to frequency, 
urinary volume, and any feelings of discomfort. Particular 
attention must also be paid to the urination behavior of the 
female patient, because incorrect hygiene procedures can 
easily enable passage of enteric bacteria to the female uro-
genital region, with consequent reinfection.4 This aspect, 
well known to nursing staff, should not be overlooked by the International Journal of General Medicine 2011:4 submit your manuscript | www.dovepress.com
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general practitioner and must be kept in mind particularly 
in elderly or less able patients.97 Re-education of the patient 
and/or caregivers can help to prevent or at least reduce the 
recurrence of UTI.
The use of urinary charts (voiding diaries) could prove 
useful even in unspecialized settings and help the   practitioner 
to overcome the difficulties of imprecise reporting by 
patients. These can be presented to the patient and be taken 
home, in order to give the woman an opportunity to think 
about her problem in a more comfortable setting and answer 
questions sincerely and openly.
A subsequent evaluation some days later, together 
with the results of investigations (such as urinalysis, and 
culture and sensitivity) will clarify whether the UTI can be 
adequately treated in general practice, or if there are compli-
cations requiring specialist referral. Either way, prescription 
of broad-spectrum therapy without attempting to identify the 
causative pathogen should be avoided. General symptoms 
are not reliable enough to enable diagnosis of UTI without 
culture and sensitivity analysis.98
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